217 related articles for article (PubMed ID: 7516821)
1. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins.
van Oosterhout YV; van den Herik-Oudijk IE; Wessels HM; de Witte T; van de Winkel JG; Preijers FW
Cancer Res; 1994 Jul; 54(13):3527-32. PubMed ID: 7516821
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
[TBL] [Abstract][Full Text] [Related]
4. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
5. Interaction of human monocyte Fc gamma receptors with rat IgG2b. A new indicator for the Fc gamma RIIa (R-H131) polymorphism.
Haagen IA; Geerars AJ; Clark MR; van de Winkel JG
J Immunol; 1995 Feb; 154(4):1852-60. PubMed ID: 7836769
[TBL] [Abstract][Full Text] [Related]
6. Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes.
Bredius RG; Fijen CA; De Haas M; Kuijper EJ; Weening RS; Van de Winkel JG; Out TA
Immunology; 1994 Dec; 83(4):624-30. PubMed ID: 7875742
[TBL] [Abstract][Full Text] [Related]
7. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
[TBL] [Abstract][Full Text] [Related]
8. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use.
Lambert JM; Goldmacher VS; Collinson AR; Nadler LM; Blättler WA
Cancer Res; 1991 Dec; 51(23 Pt 1):6236-42. PubMed ID: 1718599
[TBL] [Abstract][Full Text] [Related]
9. Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies.
Vuist WM; van Buitenen F; Hekman A; Melief CJ
Cancer Res; 1990 Sep; 50(18):5767-72. PubMed ID: 1697500
[TBL] [Abstract][Full Text] [Related]
10. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
Würflein D; Dechant M; Stockmeyer B; Tutt AL; Hu P; Repp R; Kalden JR; van de Winkel JG; Epstein AL; Valerius T; Glennie M; Gramatzki M
Cancer Res; 1998 Jul; 58(14):3051-8. PubMed ID: 9679970
[TBL] [Abstract][Full Text] [Related]
11. Mapping epitopes of human Fc gamma RII (CDw32) with monoclonal antibodies and recombinant receptors.
Ierino FL; Hulett MD; McKenzie IF; Hogarth PM
J Immunol; 1993 Mar; 150(5):1794-803. PubMed ID: 7679695
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
Haagen IA; Geerars AJ; Bast EJ; de Gast GC; van de Winkel JG; de Lau WB
Ther Immunol; 1994 Oct; 1(5):279-87. PubMed ID: 7584502
[TBL] [Abstract][Full Text] [Related]
13. Fc gamma receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody.
Vervoordeldonk SF; Merle PA; van Leeuwen EF; van der Schoot CE; von dem Borne AE; Slaper-Cortenbach IC
Blood; 1994 Mar; 83(6):1632-9. PubMed ID: 7510146
[TBL] [Abstract][Full Text] [Related]
14. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
15. Functional analysis of human Fc gamma RII (CD32) isoforms expressed in B lymphocytes.
Van Den Herik-Oudijk IE; Westerdaal NA; Henriquez NV; Capel PJ; Van De Winkel JG
J Immunol; 1994 Jan; 152(2):574-85. PubMed ID: 8283039
[TBL] [Abstract][Full Text] [Related]
16. Characterization and crystallization of soluble human Fc gamma receptor II (CD32) isoforms produced in insect cells.
Sondermann P; Jacob U; Kutscher C; Frey J
Biochemistry; 1999 Jun; 38(26):8469-77. PubMed ID: 10387093
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
Shen GL; Li JL; Ghetie MA; Ghetie V; May RD; Till M; Brown AN; Relf M; Knowles P; Uhr JW
Int J Cancer; 1988 Nov; 42(5):792-7. PubMed ID: 3263328
[TBL] [Abstract][Full Text] [Related]
18. Signal transduction via Fc gamma R and Mac-1 alpha-chain in monocytes and polymorphonuclear leucocytes.
Gadd SJ; Eher R; Majdic O; Knapp W
Immunology; 1994 Apr; 81(4):611-7. PubMed ID: 8039812
[TBL] [Abstract][Full Text] [Related]
19. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
[TBL] [Abstract][Full Text] [Related]
20. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.
Alegre ML; Tso JY; Sattar HA; Smith J; Desalle F; Cole M; Bluestone JA
J Immunol; 1995 Aug; 155(3):1544-55. PubMed ID: 7636216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]